The Next 340B Battle: Discount Duplication With Medicare Negotiated Prices

 
• By Cathy Kelly

Manufacturers likely will have to determine when to provide a 340B discount on a drug assigned a Medicare negotiated price under CMS guidance. PhRMA anticipates the job will not be easy.

The IRA Could Drive Manufacturers To Increase Pressure On Hospitals For 340B Transparency. • Source: Shutterstock

More from Market Access

More from Pink Sheet